# Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

> **NCT04105374** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **NRG Oncology**

## Conditions studied

- Anaplastic Astrocytoma
- Glioblastoma
- Oligodendroglioma
- Supratentorial Glioblastoma

## Interventions

- **DRUG:** Extended Release Flucytosine
- **DEVICE:** NovoTTF-100A Device
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **RADIATION:** Radiation Therapy
- **DRUG:** Temozolomide
- **PROCEDURE:** Therapeutic Conventional Surgery
- **BIOLOGICAL:** Vocimagene Amiretrorepvec

## Key facts

- **NCT ID:** NCT04105374
- **Lead sponsor:** NRG Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-01-31
- **Primary completion:** 2025-11-30
- **Final completion:** 2030-11-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** NCI approval withdrawn
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04105374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04105374, "Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-07-23 from https://api.ai-analytics.org/clinical/NCT04105374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*